Capital increase at Genmab as a result of the exercise of employee option rights

Company announcement

COPENHAGEN, Denmark; September 10, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 11,729 shares as a result of the exercise of employee warrants.

The increase will be made without any subscription rights for the Company’s existing shareholders or others. The shares will be subscribed for in cash at the following price of nominally DKK 1 per share:

4,623 shares at DKK 1,025.00,
3,656 shares at DKK 1,032.00,
561 shares at DKK 1,050.00,
1,645 shares at DKK 1,334.50,
1,015 shares at DKK 1,432.00 and
229 shares at DKK 1,615.00.

The proceeds for the company amount to approximately DKK 13.1 million. The increase corresponds to approximately 0.02% of the company’s share capital.

The new shares are ordinary shares without special rights and are freely transferable commercial securities. The new shares carry dividend rights and other rights against the company from the date of subscription. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Trading Authority. The capital increase is expected to be completed shortly.

Pursuant to Section 32 of the Danish Capital Markets Act No. 198 of 26 February 2024, it is hereby announced that the total nominal value of the share capital of Genmab A/S following the capital increase is DKK 66,176,831, consisting of 66,176,831 shares with a nominal value of DKK 1 each, corresponding to 66,176,831 votes.

About Genmab
Genmab is an international biotechnology company whose core goal is to lead its tireless team to improve the lives of patients with innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has been inventing next-generation antibody technology platforms, leveraging translational, quantitative and data science, resulting in a proprietary pipeline that includes bispecific T cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to improve the lives of people with cancer and other serious diseases with mind-blowing (KYSO)^®) Antibody drugs.

Founded in 1999, Genmab is headquartered in Copenhagen, Denmark, and has international operations in North America, Europe, and Asia Pacific. For more information, visit Genmab.com. Follow us on LinkedIn and X.

Contact:
Marisol Peron, Senior Vice President, Global Communications and Corporate Affairs
T: +1 609 524 0065; E: [email protected]

The story continues

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: [email protected]

This company release contains forward-looking statements. The words “believe,” “expect,” “anticipate,” “intend,” and “plan” and similar expressions identify forward-looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by these statements. Important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties associated with the outcome and conduct of clinical trials, including unforeseen safety issues, uncertainties associated with product manufacturing, lack of market acceptance of our products, our inability to manage growth, the competitive environment related to our business and markets, our inability to attract and retain appropriately qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliates, changes and developments in technology that may render our products or technologies obsolete, and other factors. For a further discussion of these risks, see the risk management sections in Genmab’s most recent financial reports, which are available at www.genmab.com and the risk factors contained in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), available at www.sec.gov. Genmab undertakes no obligation to update or revise any forward-looking statements in this corporate announcement or to confirm such statements to reflect subsequent events or circumstances after the date of the announcement or to reflect actual results, except as required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab^®; the Y-shaped Genmab logo^®; Genmab in combination with the Y-shaped Genmab logo^®; HuMax^®; DuoBody^®; HexaBody^®; DuoHexaBody^®HexElect^® and KYSO^®.

Company Announcement No. 56
CVR No.: 2102 3884
LEI code 529900MTJPDPE4MHJ122

Genmab A/S
Carl Jacobsen’s Road 30
2500 Valby
Denmark

Attachment